scholarly journals Salvadora persica: Nature’s Gift for Periodontal Health

Antioxidants ◽  
2021 ◽  
Vol 10 (5) ◽  
pp. 712
Author(s):  
Mohamed Mekhemar ◽  
Mathias Geib ◽  
Manoj Kumar ◽  
Radha ◽  
Yasmine Hassan ◽  
...  
Keyword(s):  
Clinical Trials ◽  
Periodontal Therapy ◽  
Periodontal Treatment ◽  
Oral Disease ◽  
Salvadora Persica ◽  
Periodontal Health ◽  
Clinical Investigations ◽  
Therapeutic Mechanisms ◽  
Pharmacologic Actions

Salvadora persica (SP) extract, displays very valuable biotherapeutic capacities such as antimicrobial, antioxidant, antiparasitic and anti-inflammatory effects. Numerous investigations have studied the pharmacologic actions of SP in oral disease therapies but its promising outcomes in periodontal health and treatment are not yet entirely described. The current study has been planned to analyze the reported effects of SP as a support to periodontal therapy to indorse regeneration and healing. In consort with clinical trials, in vitro investigations show the advantageous outcomes of SP adjunctive to periodontal treatment. Yet, comprehensive supplementary preclinical and clinical investigations at molecular and cellular levels are indispensable to reveal the exact therapeutic mechanisms of SP and its elements for periodontal health and therapy.

scholarly journals Nigella sativa and Thymoquinone: A Natural Blessing for Periodontal Therapy

Antioxidants ◽  
2020 ◽  
Vol 9 (12) ◽  
pp. 1260
Author(s):  
Mohamed Mekhemar ◽  
Yasmine Hassan ◽  
Christof Dörfer
Keyword(s):  
Nigella Sativa ◽  
Periodontal Regeneration ◽  
Periodontal Therapy ◽  
Periodontal Treatment ◽  
Oral Diseases ◽  
Active Constituent ◽  
Beneficial Effects ◽  
Action Mechanisms ◽  
Clinical Experiments

Thymoquinone (TQ), the chief active constituent of Nigella sativa (NS), shows very valuable biomedical properties such as antioxidant, antimicrobial, anticancer, anti-inflammatory, antihypertensive, hypoglycemic, antiparasitic and anti-asthmatic effects. Several studies have examined the pharmacological actions of TQ in the treatment of oral diseases but its potential role in periodontal therapy and regeneration is not yet fully defined. The present investigation has been designed to review the scientific studies about the effects of TQ as an adjunct to periodontal treatment to promote healing and periodontal regeneration. Along with clinical experiments, in vitro studies exhibit the beneficial effects of TQ during periodontal therapy. Nevertheless, additional comprehensive clinical and preclinical studies at cellular and molecular levels are essential to examine the particular action mechanisms of Nigella sativa and its elements, particularly TQ, during periodontal treatment or regeneration.

scholarly journals The role of maintenance in periodontal disease

Dental Update ◽  
2019 ◽  
Vol 46 (10) ◽  
pp. 959-965
Author(s):  
Joanna Batt ◽  
Phil Ower ◽  
Praveen Sharma
Keyword(s):  
Periodontal Disease ◽  
Clinical Relevance ◽  
Tooth Loss ◽  
Initial Therapy ◽  
Periodontal Therapy ◽  
Periodontal Treatment ◽  
New Classification ◽  
Periodontal Health ◽  
Periodontal Breakdown

There is increasing recognition, made explicit in the new classification for periodontitis, that periodontitis is a lifelong disease that is not ‘cured’ but rather ‘managed’. This paper focuses on how the response to periodontal treatment is ideally measured and how decisions are made as to whether the treatment has been ‘successful’ or not. The roles of both the patient and practitioner in the maintenance of periodontal health for those patients who respond to initial therapy are crucial. Patients not responding to initial, non-surgical periodontal therapy also need to be appropriately managed, as outlined in this paper. CPD/Clinical Relevance: This paper highlights the importance of maintenance of periodontal health, as an integral part of the overall management of patients with periodontitis, in order to minimize further periodontal breakdown and eventual tooth loss.

scholarly journals Contribution of Statins towards Periodontal Treatment: A Review

2019 ◽  
Vol 2019 ◽  
pp. 1-33 ◽  
Author(s):  
Catherine Petit ◽  
Fareeha Batool ◽  
Isaac Maximiliano Bugueno ◽  
Pascale Schwinté ◽  
Nadia Benkirane-Jessel ◽  
...  
Keyword(s):  
Host Response ◽  
Periodontal Therapy ◽  
Periodontal Treatment ◽  
Bacterial Clearance ◽  
Systemic Delivery ◽  
Periodontal Inflammation ◽  
Immune Mediated ◽  
Periodontal Healing

The pleiotropic effects of statins have been evaluated to assess their potential benefit in the treatment of various inflammatory and immune-mediated diseases including periodontitis. Herein, the adjunctive use of statins in periodontal therapy in vitro, in vivo, and in clinical trials was reviewed. Statins act through several pathways to modulate inflammation, immune response, bone metabolism, and bacterial clearance. They control periodontal inflammation through inhibition of proinflammatory cytokines and promotion of anti-inflammatory and/or proresolution molecule release, mainly, through the ERK, MAPK, PI3-Akt, and NF-κB pathways. Moreover, they are able to modulate the host response activated by bacterial challenge, to prevent inflammation-mediated bone resorption and to promote bone formation. Furthermore, they reduce bacterial growth, disrupt bacterial membrane stability, and increase bacterial clearance, thus averting the exacerbation of infection. Local statin delivery as adjunct to both nonsurgical and surgical periodontal therapies results in better periodontal treatment outcomes compared to systemic delivery. Moreover, combination of statin therapy with other regenerative agents improves periodontal healing response. Therefore, statins could be proposed as a potential adjuvant to periodontal therapy. However, optimization of the combination of their dose, type, and carrier could be instrumental in achieving the best treatment response.

RNAi-based gene therapy provides a wide variety of applications. Safe, biodegradable nano delivery vectors are still needed

2021 ◽  
Author(s):  
Moataz Dowaidar
Keyword(s):  
Clinical Trials ◽  
Target Genes ◽  
Endosomal Escape ◽  
Cell Uptake ◽  
Clinical Investigations ◽  
Wide Range ◽  
Production Techniques ◽  
High Degree

The considerable influence of siRNA and shRNA in controlling CRC by activating apoptosis and preventing CRC formation has been proven in vitro and in vivo research. Furthermore, the combined actions of inhibitors and RNAi-mediated gene knockdown may result in novel cancer therapy approaches.RNAi-based approaches give a wide range of prospective applications and a high degree of freedom to manipulate heretofore "unhackable" targets. However, in clinical investigations, RNAi medications are a major challenge to overcome. Furthermore, compared to other cancers such as melanoma, colon cancer has seen fewer clinical trials due to its tissue complexity. While new delivery strategies and materials are being investigated to increase distribution efficiency, randomized controlled trials must be done before treatment recommendations utilize RNAi. Safe, biodegradable and biocompatible NP delivery systems are still needed. Repeatable and simple batch production techniques for clinical trials and regulatory evaluations need to be created. Since unmodified siRNAs have limited cell uptake, they must be conjugated or complexed with suitable carrier systems. Furthermore, by combining siRNAs with adaptive and biocompatible nonviral carriers, the short half-life of siRNAs may be regulated due to their quick plasma and cell cytoplasm breakdown. Clinical trials should be explored with improved techniques to enhance RNAi medication encapsulation in lipid-based NPs such as liposomes or biodegradable polymers such as PLGA, cellular uptake and endosomal escape in mCRC cells. Advances in nanotechnology and medicinal chemistry may help address these issues, and adoption of RNAi-based therapeutics may increase.Another crucial part of employing RNAi-based therapeutics is finding suitable targets. Besides knowing target genes and pathways for CRC advancement, understanding modifying genes that compensate for the effect of target gene loss function and the degree of gene silence necessary is crucial.

Non surgical periodontal therapy: An evidence-based perspective

2021 ◽  
Vol 3 (2) ◽  
pp. 48-51
Author(s):  
Debarghya Pal ◽  
Farha Nasim ◽  
Himadri Chakrabarty ◽  
Abhijit Chakraborty
Keyword(s):  
Treatment Approach ◽  
Root Surface ◽  
Review Article ◽  
Periodontal Therapy ◽  
Periodontal Treatment ◽  
Etiologic Factor ◽  
Evidence Based ◽  
Scaling And Root Planing ◽  
Critical Aspect ◽  
Periodontal Health

Non surgical periodontal therapy is a critical aspect of periodontal treatment, aimed at removal of the etiologic factor, thereby halting the disease progression and re-establishment of biologically acceptable root surface for healing. With non surgical periodontal therapy, periodontal health can be achieved in the least invasive manner. In comparison to other modes of periodontal treatment, Non-surgical therapy remains the corner stone of periodontal treatment, as not only the first mode of treatment approach for treating periodontal disease but it also restores tissue health to prepare it for further surgery. Scaling and root planing have been extensively studied over decades to evaluate their efficacy, to decide on the treatment approach, to determine the criteria for assessing its adequacy to facilitate healing. This review article focuses on the studies done to bring into light the various aspects of non surgical periodontal therapy.

Effects of periodontal therapy with topical antibiotics in the glycemic control of diabetic patients: systematic review.

2019 ◽  
Vol 27 (1) ◽  
pp. 31-42
Author(s):  
Gloria Cristina Aranzazu-Moya
Keyword(s):  
Periodontal Disease ◽  
Periodontal Therapy ◽  
Periodontal Treatment ◽  
Diabetic Patients ◽  
Inclusion Criteria ◽  
Topical Antibiotics ◽  
Bias Risk ◽  
Black Scale ◽  
Glycated Hemoglobin A ◽  
Modest Reduction

Background: Periodontal disease is considered as a diabetes complication and has been suggested that periodontal treatment plus antibiotics should reduce glycated hemoglobin A, by reducing local production of pro inflammatory substances. Objective: To evaluate diabetic patients with periodontal disease under periodontal treatment plus topical antibiotics and reduction of  HbA1c, compared to diabetic patients under periodontal treatment without antibiotics. Materials and Methods: Using PUBMED, SCOPUS, WEB OF SCIENCE, EMBASE and Google Scholar data bases, were screened documents from 2008 to 2018. The documents included were the clinical studies, which included non-surgical periodontal treatment plus topical antibiotics, whose outcomes included the HbA1c report. Two independent researchers evaluate title; abstract and bias risk with Downs Black scale and Cochrane tool. Documents with a score higher than 15 on average by the two evaluators were included. Results: Five articles, which find inclusion criteria, were identified. Two documents failed to demonstrate statistically significant effect when compared to non-surgical periodontal therapy alone. Conclusion: In general a modest reduction of HbA1c was identified when using antibiotic therapy.

Modulation of Matrix Metalloproteinases by Plant-Derived Products

2020 ◽  
Vol 20 ◽  
Author(s):  
Nur Najmi Mohamad Anuar ◽  
Nurul Iman Natasya Zulkafali ◽  
Azizah Ugusman
Keyword(s):  
Clinical Trials ◽  
Natural Products ◽  
Matrix Metalloproteinases ◽  
Animal Studies ◽  
Current Knowledge ◽  
In Vitro Models ◽  
In Vivo Studies ◽  
Extracellular Matrix Components

: Matrix metalloproteinases (MMPs) are a group of zinc-dependent metallo-endopeptidase that are responsible towards the degradation, repair and remodelling of extracellular matrix components. MMPs play an important role in maintaining a normal physiological function and preventing diseases such as cancer and cardiovascular diseases. Natural products derived from plants have been used as traditional medicine for centuries. Its active compounds, such as catechin, resveratrol and quercetin, are suggested to play an important role as MMPs inhibitors, thereby opening new insights into their applications in many fields, such as pharmaceutical, cosmetic and food industries. This review summarises the current knowledge on plant-derived natural products with MMP-modulating activities. Most of the reviewed plant-derived products exhibit an inhibitory activity on MMPs. Amongst MMPs, MMP-2 and MMP-9 are the most studied. The expression of MMPs is inhibited through respective signalling pathways, such as MAPK, NF-κB and PI3 kinase pathways, which contribute to the reduction in cancer cell behaviours, such as proliferation and migration. Most studies have employed in vitro models, but a limited number of animal studies and clinical trials have been conducted. Even though plant-derived products show promising results in modulating MMPs, more in vivo studies and clinical trials are needed to support their therapeutic applications in the future.

scholarly journals Targeting RON receptor tyrosine kinase for treatment of advanced solid cancers: antibody–drug conjugates as lead drug candidates for clinical trials

2020 ◽  
Vol 12 ◽  
pp. 175883592092006
Author(s):  
Hang-Ping Yao ◽  
Sreedhar Reddy Suthe ◽  
Xiang-Min Tong ◽  
Ming-Hai Wang
Keyword(s):  
Clinical Trials ◽  
Tyrosine Kinase ◽  
Receptor Tyrosine Kinase ◽  
Targeted Therapeutics ◽  
Antibody Drug Conjugates ◽  
Drug Candidates ◽  
Drug Conjugates ◽  
Ron Receptor ◽  
Antibody Drug

The recepteur d’origine nantais (RON) receptor tyrosine kinase, belonging to the mesenchymal-to-epithelial transition proto-oncogene family, has been implicated in the pathogenesis of cancers derived from the colon, lung, breast, and pancreas. These findings lay the foundation for targeting RON for cancer treatment. However, development of RON-targeted therapeutics has not gained sufficient attention for the last decade. Although therapeutic monoclonal antibodies (TMABs) targeting RON have been validated in preclinical studies, results from clinical trials have met with limited success. This outcome diminishes pharmaceutical enthusiasm for further development of RON-targeted therapeutics. Recently, antibody–drug conjugates (ADCs) targeting RON have drawn special attention owing to their increased therapeutic activity. The rationale for developing anti-RON ADCs is based on the observation that cancer cells are not sufficiently addicted to RON signaling for survival. Thus, TMAB-mediated inhibition of RON signaling is ineffective for clinical application. In contrast, anti-RON ADCs combine a target-specific antibody with potent cytotoxins for cancer cell killing. This approach not only overcomes the shortcomings in TMAB-targeted therapies but also holds the promise for advancing anti-RON ADCs into clinical trials. In this review, we discuss the latest advancements in the development of anti-RON ADCs for targeted cancer therapy including drug conjugation profile, pharmacokinetic properties, cytotoxic effect in vitro, efficacy in tumor models, and toxicological activities in primates.

scholarly journals 1592. Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales and Pseudomonas aeruginosa With Overexpression of AmpC β-Lactamase From Phase 3 Clinical Trials

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S792-S793
Author(s):  
Lynn-Yao Lin ◽  
Dmitri Debabov ◽  
William Chang ◽  
Urania Rappo
Keyword(s):  
Clinical Trials ◽  
Active Agent ◽  
Complicated Urinary Tract Infection ◽  
Carbapenem Resistance ◽  
Vitro Activity ◽  
In Vitro Activity ◽  
Control Groups ◽  
In Vitro Susceptibility ◽  
Intra Abdominal Infection

Abstract Background AmpC overproduction is a main mechanism of carbapenem resistance, in the absence of acquired carbapenemases. Ceftazidime-avibactam (CAZ-AVI) has potent in vitro activity against AmpC-producing P. aeruginosa and Enterobacterales that are resistant to carbapenems and other β-lactams. Methods Activity of CAZ-AVI and comparators was evaluated against AmpC-overproducing Enterobacterales (n=77) and P. aeruginosa (n=53) collected from 4 CAZ-AVI clinical trials: RECLAIM (complicated intra-abdominal infection [cIAI]), REPRISE (cIAI/complicated urinary tract infection [cUTI]), RECAPTURE (cUTI) and REPROVE (hospital-acquired pneumonia/ventilator associated pneumonia). In vitro susceptibility of CAZ-AVI and comparators was performed by broth microdilution using ThermoFisher custom panels. CLSI breakpoints were used to determine susceptibility. Quantitative PCR and microarray data were used to characterize presence and expression of AmpC. Clinical response at test of cure was assessed. Results Against 77 AmpC-overproducing Enterobacterales isolates, meropenem-vaborbactam (MVB) (98.7% susceptible [S]), CAZ-AVI (96.1% S), and meropenem (MEM) (96.1% S) had similar in vitro activity (Table), with greater in vitro activity than amikacin (AMK) (84.4% S), gentamicin (61.0% S), and ceftolozane-tazobactam (TZC) (35.1% S). Clinical cures in patients with baseline AmpC-overproducing Enterobacterales were 21/26 (81%) in CAZ-AVI group vs 17/20 (85%) in control groups. Against 53 AmpC-overproducing P. aeruginosa isolates, CAZ-AVI (73.6% S) showed greater in vitro activity than AMK (69.8% S), TZC (58.5% S), and MEM (37.7% S). Clinical cures in patients with baseline AmpC-overproducing P. aeruginosa were 12/14 (86%) in CAZ-AVI group vs 9/12 (75%) in control groups. MIC distributions against the same P aeruginosa isolates were CAZ-AVI (MIC50/90, 4/ >64 µg/mL), MVB (MIC50/90, 8/32 µg/mL), and MEM (MIC50/90, 8/32 µg/mL). Table Conclusion CAZ-AVI was the most active agent against AmpC-overproducing P. aeruginosa with higher proportion of clinical cure than controls. CAZ-AVI was also among the most active agents against AmpC-overproducing Enterobacterales, with >96% isolates susceptible. Disclosures Lynn-Yao Lin, MS, AbbVie (Employee) Dmitri Debabov, PhD, AbbVie (Employee) William Chang, BS, AbbVie (Employee) Urania Rappo, MD, MS, PharmD, Allergan (before its acquisition by AbbVie) (Employee)

scholarly journals Antibiotic loaded β-tricalcium phosphate/calcium sulfate for antimicrobial potency, prevention and killing efficacy of Pseudomonas aeruginosa and Staphylococcus aureus biofilms

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Nan Jiang ◽  
Devendra H. Dusane ◽  
Jacob R. Brooks ◽  
Craig P. Delury ◽  
Sean S. Aiken ◽  
...  
Keyword(s):  
Tricalcium Phosphate ◽  
Calcium Sulfate ◽  
Bone Graft Substitute ◽  
In Vitro Assays ◽  
In Vivo Experiments ◽  
Orthopaedic Infections ◽  
Clinical Investigations ◽  
Antimicrobial Potency

AbstractThis study investigated the efficacy of a biphasic synthetic β-tricalcium phosphate/calcium sulfate (β-TCP/CS) bone graft substitute for compatibility with vancomycin (V) in combination with tobramycin (T) or gentamicin (G) evidenced by the duration of potency and the prevention and killing efficacies of P. aeruginosa (PAO1) and S. aureus (SAP231) biofilms in in vitro assays. Antibiotic loaded β-TCP/CS beads were compared with antibiotic loaded beads formed from a well characterized synthetic calcium sulfate (CS) bone void filler. β-TCP/CS antibiotic loaded showed antimicrobial potency against PAO1 in a repeated Kirby-Bauer like zone of inhibition assay for 6 days compared to 8 days for CS. However, both bead types showed potency against SAP231 for 40 days. Both formulations loaded with V + T completely prevented biofilm formation (CFU below detection limits) for the 3 days of the experiment with daily fresh inoculum challenges (P < 0.001). In addition, both antibiotic loaded materials and antibiotic combinations significantly reduced the bioburden of pre-grown biofilms by between 3 and 5 logs (P < 0.001) with V + G performing slightly better against PAO1 than V + T. Our data, combined with previous data on osteogenesis suggest that antibiotic loaded β-TCP/CS may have potential to stimulate osteogenesis through acting as a scaffold as well as simultaneously protecting against biofilm infection. Future in vivo experiments and clinical investigations are warranted to more comprehensively evaluate the use of β-TCP/CS in the management of orthopaedic infections.

Sign in / Sign up

Export Citation Format

Share Document